NM_000251.3:c.2006G>A
Variant summary
Our verdict is Likely pathogenic. Variant got 8 ACMG points: 8P and 0B. PM1PM2PM5PP3PP5
The NM_000251.3(MSH2):c.2006G>A(p.Gly669Asp) variant causes a missense, splice region change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 14/23 in silico tools predict a damaging outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. G669R) has been classified as Pathogenic.
Frequency
Consequence
NM_000251.3 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 8 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 1 Pathogenic:1
This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 23690608]. This variant is expected to disrupt protein structure [Myriad internal data]. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.G669D variant (also known as c.2006G>A) is located in coding exon 13 of the MSH2 gene. The glycine at codon 669 is replaced by aspartic acid, an amino acid with similar properties. This change occurs in the first base pair of coding exon 13. This alteration was identified in a HNPCC family and the colon tumor of the proband displayed high microsatellite instability with loss of both MSH2/MSH6 expression on immunohistochemistry (IHC) (Losi L et al. Am. J. Gastroenterol., 2005 Oct;100:2280-7; de Leon MP et al. Scand. J. Gastroenterol., 2007 Jun;42:746-53; Pedroni M et al. Dis. Markers, 2007;23:179-87). This alteration was also identified as somatic in origin in conjunction with a somatic pathogenic mutation in MSH2 in a colorectal tumor that displayed loss of both MSH2/MSH6 on IHC (Ambry internal data). In a massively parallel cell-based functional assay testing susceptibility to a DNA damaging agent, 6-thioguanine (6-TG), this variant was determined to be functionally deleterious (Jia X et al. Am J Hum Genet, 2021 Jan;108:163-175). In addition, in multiple other assays testing MSH2 function, this variant showed functionally abnormal results (Drost M et al. Proc. Natl. Acad. Sci. U.S.A., 2013 Jun;110:9403-8; Ollodart AR et al. Genetics, 2021 06;218:). Based on an internal structural assessment, this alteration disrupts the ATP-binding P-loop motif (Saraste M et al. Trends Biochem. Sci., 1990 Nov;15:430-4; Warren JJ et al. Mol. Cell, 2007 May;26:579-92). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
Lynch syndrome Uncertain:1
MSH2 NM_000251.2:c.2006G>A has a 93.3% probability of pathogenicity based on combining prior probability from public data with a likelihood ratio of 1.56 to 1, generated from evidence of seeing this as a somatic mutation in a tumor without loss of heterozygosity at the MSH2 locus. See Shirts et al 2018, PMID 29887214. -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
This sequence change replaces glycine, which is neutral and non-polar, with aspartic acid, which is acidic and polar, at codon 669 of the MSH2 protein (p.Gly669Asp). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with MSH2-related conditions. ClinVar contains an entry for this variant (Variation ID: 90852). An algorithm developed specifically for the MSH2 gene suggests that this missense change is likely to be deleterious (PMID: 18383312, 22290698). Experimental studies have shown that this missense change affects MSH2 function (PMID: 23690608, 28422960). This variant disrupts the c.2006G>T nucleotide in the MSH2 gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 10612827, 21520333, 26247049, 27629256; Invitae). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at